title: Association of RAGE gene polymorphisms with in-stent restenosis in non-diabetic Korean population.
abstract: BACKGROUND
  Interaction between advanced glycosylation end products (AGEs) and receptor for AGEs (RAGE) in vessel wall may lead to inflammation, smooth muscle cell proliferation, and extracellular matrix production, culminating in exaggerated intimal hyperplasia and restenosis. We investigated the possibility that single nucleotide polymorphisms of the genes encoding RAGE are associated with in-stent restenosis after coronary stenting.
  
  
  METHODS
  Our study included 334 consecutive non-diabetic male patients with symptomatic coronary artery disease who underwent bare metal stent implantation. Follow-up angiography was performed in 297 patients (88.9%), 6 months after intervention. We screened -1106T-->C, -443T-->C, -388T-->A, -257G-->A, +557G-->A and +1704G-->T RAGE polymorphisms in these patients. Genotyping was performed by single base extension with amplifying primers and probes for TaqMan.
  
  
  RESULTS
  A total of 355 target lesions were evaluated, in 297 patients. There was no significant association of the -1106T-->C, -443T-->C, -388T-->A, -257G-->A, +557G-->A or +1704G-->T polymorphisms with in-stent restenosis after coronary artery stenting. We did not observe a significant difference between the genotype distributions and the rates of angiographic restenosis between the polymorphisms. In a multivariate analysis of angiographic restenosis, we examined the possible influence of the baseline, lesion-related, and procedural variables. After adjustment for these potentially confounding factors, the multivariate analysis did not reveal an association of polymorphism with angiographic restenosis.
  
  
  CONCLUSIONS
  Our observation suggests that the RAGE gene polymorphism is not associated with in-stent restenosis after coronary artery stenting in non-diabetic patients in the Korean population.
authors.affiliation: Division of Cardiology, Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
authors.forename: Chi Young
authors.initials: CY
authors.lastname: Shim
authors.forename: Sungha
authors.initials: S
authors.lastname: Park
authors.forename: Se-Jung
authors.initials: SJ
authors.lastname: Yoon
authors.forename: Hyun-Young
authors.initials: HY
authors.lastname: Park
authors.forename: Hung Tae
authors.initials: HT
authors.lastname: Kim
authors.forename: Bermseok
authors.initials: B
authors.lastname: Oh
authors.forename: Chanmi
authors.initials: C
authors.lastname: Park
authors.forename: Young-Guk
authors.initials: YG
authors.lastname: Ko
authors.forename: Donghoon
authors.initials: D
authors.lastname: Choi
authors.forename: Yangsoo
authors.initials: Y
authors.lastname: Jang
authors.forename: Namsik
authors.initials: N
authors.lastname: Chung
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D023903:Coronary Restenosis / Q000209:etiology / Q000235:genetics*; D023921:Coronary Stenosis / Q000628:therapy; D017127:Glycation End Products, Advanced; D006801:Humans; D007723:Korea; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000235:genetics*; D015607:Stents / Q000009:adverse effects*
chemical_list: D017127:Glycation End Products, Advanced; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic